• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Mol Cell . Functional landscape of SARS-CoV-2 cellular restriction

tetano

Editor, Senior Moderator
Mol Cell


. 2021 Apr 13;S1097-2765(21)00313-0.
doi: 10.1016/j.molcel.2021.04.008. Online ahead of print.
Functional landscape of SARS-CoV-2 cellular restriction


Laura Martin-Sancho[SUP] 1 [/SUP], Mary K Lewinski[SUP] 2 [/SUP], Lars Pache[SUP] 1 [/SUP], Charlotte A Stoneham[SUP] 2 [/SUP], Xin Yin[SUP] 1 [/SUP], Mark E Becker[SUP] 3 [/SUP], Dexter Pratt[SUP] 4 [/SUP], Christopher Churas[SUP] 4 [/SUP], Sara B Rosenthal[SUP] 4 [/SUP], Sophie Liu[SUP] 4 [/SUP], Stuart Weston[SUP] 5 [/SUP], Paul D De Jesus[SUP] 1 [/SUP], Alan M O'Neill[SUP] 6 [/SUP], Anshu P Gounder[SUP] 1 [/SUP], Courtney Nguyen[SUP] 1 [/SUP], Yuan Pu[SUP] 1 [/SUP], Heather M Curry[SUP] 1 [/SUP], Aaron L Oom[SUP] 2 [/SUP], Lisa Miorin[SUP] 7 [/SUP], Ariel Rodriguez-Frandsen[SUP] 1 [/SUP], Fan Zheng[SUP] 4 [/SUP], Chunxiang Wu[SUP] 8 [/SUP], Yong Xiong[SUP] 8 [/SUP], Matthew Urbanowski[SUP] 9 [/SUP], Megan L Shaw[SUP] 10 [/SUP], Max W Chang[SUP] 4 [/SUP], Christopher Benner[SUP] 4 [/SUP], Thomas J Hope[SUP] 3 [/SUP], Matthew B Frieman[SUP] 5 [/SUP], Adolfo Garc?a-Sastre[SUP] 11 [/SUP], Trey Ideker[SUP] 12 [/SUP], Judd F Hultquist[SUP] 13 [/SUP], John Guatelli[SUP] 2 [/SUP], Sumit K Chanda[SUP] 14 [/SUP]



Affiliations

Abstract

A deficient interferon (IFN) response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been implicated as a determinant of severe coronavirus disease 2019 (COVID-19). To identify the molecular effectors that govern IFN control of SARS-CoV-2 infection, we conducted a large-scale gain-of-function analysis that evaluated the impact of human IFN-stimulated genes (ISGs) on viral replication. A limited subset of ISGs were found to control viral infection, including endosomal factors inhibiting viral entry, RNA binding proteins suppressing viral RNA synthesis, and a highly enriched cluster of endoplasmic reticulum (ER)/Golgi-resident ISGs inhibiting viral assembly/egress. These included broad-acting antiviral ISGs and eight ISGs that specifically inhibited SARS-CoV-2 and SARS-CoV-1 replication. Among the broad-acting ISGs was BST2/tetherin, which impeded viral release and is antagonized by SARS-CoV-2 Orf7a protein. Overall, these data illuminate a set of ISGs that underlie innate immune control of SARS-CoV-2/SARS-CoV-1 infection, which will facilitate the understanding of host determinants that impact disease severity and offer potential therapeutic strategies for COVID-19.

Keywords: BST2; ISG; Orf7a; SARS-CoV-2; innate immunity; interferon; viral evasion.
 
Back
Top Bottom